MGO One Seven LLC Buys 79,085 Shares of Medtronic PLC $MDT

MGO One Seven LLC grew its holdings in shares of Medtronic PLC (NYSE:MDT) by 374.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 100,206 shares of the medical technology company’s stock after buying an additional 79,085 shares during the quarter. MGO One Seven LLC’s holdings in Medtronic were worth $9,544,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of MDT. Delos Wealth Advisors LLC purchased a new position in Medtronic during the 2nd quarter valued at about $27,000. Corundum Trust Company INC purchased a new stake in Medtronic during the third quarter worth $27,000. Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Medtronic during the 3rd quarter worth $33,000. Tripletail Wealth Management LLC purchased a new stake in shares of Medtronic during the third quarter valued at about $34,000. Finally, GFG Capital LLC bought a new position in shares of Medtronic during the 2nd quarter worth approximately $36,000. Institutional investors own 82.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. William Blair upgraded Medtronic from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 6th. Daiwa Capital Markets increased their price target on shares of Medtronic from $104.00 to $117.00 and gave the stock a “buy” rating in a report on Tuesday, November 25th. Stifel Nicolaus boosted their price objective on Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a report on Thursday, October 9th. Leerink Partners set a $120.00 price target on Medtronic and gave the company an “outperform” rating in a report on Wednesday, November 19th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eleven have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $110.28.

Medtronic Price Performance

NYSE:MDT opened at $97.54 on Monday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The stock has a 50 day moving average price of $98.31 and a 200 day moving average price of $94.57. The stock has a market cap of $125.04 billion, a PE ratio of 26.29, a P/E/G ratio of 2.57 and a beta of 0.71. Medtronic PLC has a one year low of $79.55 and a one year high of $106.33.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.31 by $0.05. The business had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Stockholders of record on Friday, December 26th will be paid a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, December 26th. Medtronic’s dividend payout ratio is 76.55%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).